|1.||Xu, Linping: 1 article (01/2015)|
|2.||Zhang, Yong: 1 article (01/2015)|
|3.||Gao, Quanli: 1 article (01/2015)|
|4.||Mai, Ling: 1 article (01/2015)|
|5.||Li, Wei: 1 article (01/2015)|
|6.||Wang, Yaomei: 1 article (01/2015)|
|7.||Zhao, Lingdi: 1 article (01/2015)|
|8.||Thirion, Christian: 1 article (04/2014)|
|9.||Atkinson, Mike J: 1 article (04/2014)|
|10.||Salomon, M: 1 article (04/2014)|
|1.||Brain Neoplasms (Brain Tumor)
01/01/2015 - "The aim of this study was to investigate the clinical efficacy of RetroNectin-activated cytokine-induced killer cell (R-CIK) therapy following conventional therapies in patients with metastatic brain tumors. "
01/01/2015 - "Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients."
04/01/2014 - "For clinical applications the need for optimized transduction protocols and the limited activity of retronectin as LV enhancer, results in the application of a high multiplicity of infection (MOI) to achieve effective transduction efficiencies for a number of therapeutically relevant cells, e.g. "
05/01/2011 - "When cells were transduced for 6 h in the presence of mSCF, hTPO and FLT3-L in retronectin-coated dishes at a multiplicity of infection of 10 transduction units/cell, up to 70% of granulo-macrophage colony-forming cells expressed the EGFP reporter gene. "
01/01/2009 - "Using commercially available G-CSF mobilized peripheral blood (PB) CD34(+) cells as the most clinically relevant target, we systematically examined factors including the use of serum, cytokine combinations, pre-stimulation time, multiplicity of infection (MOI), transduction duration and the use of spinoculation and/or retronectin. "
07/20/1999 - "Retroviral infection of CD34+ cells was performed by culture on fibronectin fragment CH-296 (RetroNectin, RN), using the truncated human nerve growth factor receptor (NGFR) as the transgene reporter. "
04/01/2006 - "We demonstrated that gene transfer using a combination of G protein of vesicular stomatitis virus-pseudotyped retroviral vector and retronectin introduced COL7A1 into keratinocytes and fibroblasts from a DEB patient with the lack of COL7A1 expression. "
05/01/2001 - "An MSCV based retroviral vector with the gene for enhanced green fluorescent protein (MGIN) produced by GP+envAM12 (amphotropic envelope), PG13 (gibbon ape leukemia virus envelope) or 293GPG (vesicular stomatitis virus envelope) cell lines was used to transduce cord blood CD34+ cells on Retronectin (fibronectin fragment CH-296) in three different ways: either in vector containing medium (VCM), in fresh medium on Retronectin pre-loaded with vector or in VCM on Retronectin pre-loaded with vector. "
|5.||Lung Neoplasms (Lung Cancer)
|2.||Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)
|3.||GTP-Binding Proteins (G-Protein)
|4.||Muromonab-CD3 (Muromonab CD3)
|5.||Granulocyte Colony-Stimulating Factor (G-CSF)
|6.||Antigen Receptors (Antigen Receptor)
|8.||enhanced green fluorescent protein